禁煙&ニコチン中毒の世界市場

◆英語タイトル:Global Smoking Cessation and Nicotine De-addiction MARKET 2020-2024
◆商品コード:IRTNTR40398
◆発行会社(リサーチ会社):Technavio
◆発行日:2020年1月31日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Global Smoking Cessation And Nicotine De-addiction Market 2020-2024Technavio has been monitoring the global smoking cessation and nicotine de-addiction market and it is poised to grow by USD 16.6 bn during 2020-2024, progressing at a CAGR of 13% during the forecast period. Our reports on global smoking cessation and nicotine de-addiction market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing number of people trying to quit smoking.In addition, product innovations is anticipated to boost the growth of the global smoking cessation and nicotine de-addiction market as well.
Market Segmentation
Technavio’s global smoking cessation and nicotine de-addiction market is segmented as below:
Product:
o E-cigarette

o NRT

o Drug Therapy

Geographic Segmentation:
o APAC

o Europe

o MEA

o North America

o South America

Key Trends for global smoking cessation and nicotine de-addiction market growth
This study identifies product innovations as the prime reasons driving the global smoking cessation and nicotine de-addiction market growth during the next few years.
Prominent vendors in global smoking cessation and nicotine de-addiction market
We provide a detailed analysis of around 25 vendors operating in the global smoking cessation and nicotine de-addiction market, including some of the vendors such as British American Tobacco Plc, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Plc, Imperial Brands Plc, Japan Tobacco Inc., Johnson & Johnson Services Inc., JUUL Labs Inc., Pfizer Inc. and Philip Morris International Inc. .
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/Global–Smoking-Cessation-and-Nicotine-De-Addiction -Market-industry-analysis

About Technavio
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product placement
o E-cigarette – Market size and forecast 2019-2024
o NRT – Market size and forecast 2019-2024
o Drug therapy – Market size and forecast 2019-2024
o Market opportunity by Product
• Customer landscape
o Overview
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o APAC – Market size and forecast 2019-2024
o South America – Market size and forecast 2019-2024
o MEA – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
• Drivers, Challenges, and Trends
o Market drivers
o Volume driver – Demand led growth
o Volume driver – Supply led growth
o Volume driver – External factors
o Volume driver – Demand shift in adjacent markets
o Price driver – Inflation
o Price driver – Shift from lower to higher priced units
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o British American Tobacco Plc
o Cipla Ltd.
o Dr. Reddy’s Laboratories Ltd.
o GlaxoSmithKline Plc
o Imperial Brands Plc
o Japan Tobacco Inc.
o Johnson & Johnson Services Inc.
o JUUL Labs Inc.
o Pfizer Inc.
o Philip Morris International Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
• Exhibits
• 1.Key Finding 1
• 2.Key Finding 2
• 3.Key Finding 3
• 4.Key Finding 4
• 5.Key Finding 5
• 6.Key Finding 6
• 7.Key Finding 7
• 8.Market in focus
• 9.Parent market
• 10.Market characteristics
• 11.Product / Service portfolio of key vendors included in the market definition
• 12.Market segments
• 13.Global – Market size and forecast 2019 – 2024 ($ billion)
• 14.Global market: Year-over-year growth 2019 – 2024 (%)
• 15.Five forces analysis 2019 & 2024
• 16.Bargaining power of buyers
• 17.Bargaining power of suppliers
• 18.Threat of new entrants
• 19.Threat of substitutes
• 20.Threat of rivalry
• 21.Market condition – Five forces 2019
• 22.Product placement – Market share 2019-2024 (%)
• 23.Comparison by Product placement
• 24.E-cigarette – Market size and forecast 2019-2024 ($ billion)
• 25.E-cigarette – Year-over-year growth 2019-2024 (%)
• 26.NRT – Market size and forecast 2019-2024 ($ billion)
• 27.NRT – Year-over-year growth 2019-2024 (%)
• 28.Drug therapy – Market size and forecast 2019-2024 ($ billion)
• 29.Drug therapy – Year-over-year growth 2019-2024 (%)
• 30. Market opportunity by Product
• 31.Customer landscape
• 32.Market share by geography 2019-2024 (%)
• 33.Geographic comparison
• 34.North America – Market size and forecast 2019-2024 ($ billion)
• 35.North America – Year-over-year growth 2019-2024 (%)
• 36.Europe – Market size and forecast 2019-2024 ($ billion)
• 37.Europe – Year-over-year growth 2019-2024 (%)
• 38.APAC – Market size and forecast 2019-2024 ($ billion)
• 39.APAC – Year-over-year growth 2019-2024 (%)
• 40.South America – Market size and forecast 2019-2024 ($ billion)
• 41.South America – Year-over-year growth 2019-2024 (%)
• 42.MEA – Market size and forecast 2019-2024 ($ billion)
• 43.MEA – Year-over-year growth 2019-2024 (%)
• 44.Key leading countries
• 45.Market opportunity by geography ($ billion)
• 46.Impact of drivers
• 47.Impact of challenges
• 48.Landscape disruption
• 49.Industry risks
• 50.Vendors covered
• 51.Market positioning of vendors
• 52.British American Tobacco Plc – Overview (1/3)
• 53.British American Tobacco Plc – Overview (2/3)
• 54.British American Tobacco Plc – Overview (3/3)
• 55.British American Tobacco Plc – Product and service
• 56.British American Tobacco Plc – Key offerings
• 57.British American Tobacco Plc – Key customers
• 58.British American Tobacco Plc – Segment focus
• 59.Cipla Ltd. – Overview (1/3)
• 60.Cipla Ltd. – Overview (2/3)
• 61.Cipla Ltd. – Overview (3/3)
• 62.Cipla Ltd. – Business segments
• 63.Cipla Ltd. – Key offerings
• 64.Cipla Ltd. – Key customers
• 65.Cipla Ltd. – Segment focus
• 66.Dr. Reddy’s Laboratories Ltd. – Overview (1/3)
• 67.Dr. Reddy’s Laboratories Ltd. – Overview (2/3)
• 68.Dr. Reddy’s Laboratories Ltd. – Overview (3/3)
• 69.Dr. Reddy’s Laboratories Ltd. – Business segments
• 70.Dr. Reddy’s Laboratories Ltd. – Key offerings
• 71.Dr. Reddy’s Laboratories Ltd. – Key customers
• 72.Dr. Reddy’s Laboratories Ltd. – Segment focus
• 73.GlaxoSmithKline Plc – Overview (1/3)
• 74.GlaxoSmithKline Plc – Overview (2/3)
• 75.GlaxoSmithKline Plc – Overview (3/3)
• 76.GlaxoSmithKline Plc – Business segments
• 77.GlaxoSmithKline Plc – Key offerings
• 78.GlaxoSmithKline Plc – Key customers
• 79.GlaxoSmithKline Plc – Segment focus
• 80.Imperial Brands Plc – Overview (1/3)
• 81.Imperial Brands Plc – Overview (2/3)
• 82.Imperial Brands Plc – Overview (3/3)
• 83.Imperial Brands Plc – Business segments
• 84.Imperial Brands Plc – Key offerings
• 85.Imperial Brands Plc – Key customers
• 86.Imperial Brands Plc – Segment focus
• 87.Japan Tobacco Inc. – Overview (1/3)
• 88.Japan Tobacco Inc. – Overview (2/3)
• 89.Japan Tobacco Inc. – Overview (3/3)
• 90.Japan Tobacco Inc. – Business segments
• 91.Japan Tobacco Inc. – Key offerings
• 92.Japan Tobacco Inc. – Key customers
• 93.Japan Tobacco Inc. – Segment focus
• 94.Johnson & Johnson Services Inc. – Overview (1/3)
• 95.Johnson & Johnson Services Inc. – Overview (2/3)
• 96.Johnson & Johnson Services Inc. – Overview (3/3)
• 97.Johnson & Johnson Services Inc. – Business segments
• 98.Johnson & Johnson Services Inc. – Key offerings
• 99.Johnson & Johnson Services Inc. – Key customers
• 100.Johnson & Johnson Services Inc. – Segment focus
• 101.JUUL Labs Inc. – Overview (1/3)
• 102.JUUL Labs Inc. – Overview (2/3)
• 103.JUUL Labs Inc. – Overview (3/3)
• 104.JUUL Labs Inc. – Product and service
• 105.JUUL Labs Inc. – Key offerings
• 106.JUUL Labs Inc. – Key customers
• 107.JUUL Labs Inc. – Segment focus
• 108.Pfizer Inc. – Overview (1/3)
• 109.Pfizer Inc. – Overview (2/3)
• 110.Pfizer Inc. – Overview (3/3)
• 111.Pfizer Inc. – Business segments
• 112.Pfizer Inc. – Key offerings
• 113.Pfizer Inc. – Key customers
• 114.Pfizer Inc. – Segment focus
• 115.Philip Morris International Inc. – Overview (1/3)
• 116.Philip Morris International Inc. – Overview (2/3)
• 117.Philip Morris International Inc. – Overview (3/3)
• 118.Philip Morris International Inc. – Business segments
• 119.Philip Morris International Inc. – Key offerings
• 120.Philip Morris International Inc. – Key customers
• 121.Philip Morris International Inc. – Segment focus
• 122.Currency conversion rates for US$
• 123.Research Methodology
• 124.Validation techniques employed for market sizing
• 125.Information sources
• 126.List of abbreviations



【掲載企業】

British American Tobacco Plc,Cipla Ltd.,Dr. Reddy's Laboratories Ltd.,GlaxoSmithKline Plc,Imperial Brands Plc,Japan Tobacco Inc.,Johnson & Johnson Services Inc.,JUUL Labs Inc.,Pfizer Inc.,Philip Morris International Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[禁煙&ニコチン中毒の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆